Remyelination News and Research

RSS

Remyelination is a term for the re-generation of the nerve's myelin sheath, damaged in many diseases such as multiple sclerosis (MS) and the leukodystrophies. Remyelination is a subject of active medical research.

Researchers reveal molecular mechanism that controls remyelination

Researchers in Japan have revealed the molecular mechanism involved in the process of repair to damage of the myelin sheath. In vertebrates, axons extending from nerve cells are covered by insulating sheets called the myelin sheath, made with the cell membranes of oligodendrocytes, enabling fast electrical signaling through saltatory conduction.

4 Sep 2015

Several drugs could lead to new MS treatment options

New research published this week in Nature has found several drugs could lead to new treatment options for multiple sclerosis (MS), including two drugs that effectively treat MS at the source, in vivo. When administered at the peak of disease, these two drugs showed a striking reversal of disease severity.

23 Apr 2015

Two existing drugs may potentially become new drug target for multiple sclerosis

Two drugs already on the market -- an antifungal and a steroid -- may potentially take on new roles as treatments for multiple sclerosis. According to a study published in Nature today, researchers discovered that these drugs may activate stem cells in the brain to stimulate myelin producing cells and repair white matter, which is damaged in multiple sclerosis.

20 Apr 2015

New longer-term data on Genzyme's relapsing MS treatments to be presented at AAN 2015

Genzyme, a Sanofi company, announced today that new longer-term data on its relapsing multiple sclerosis treatments, Aubagio (teriflunomide) and Lemtrada (alemtuzumab), will be featured during the 67th annual meeting of the American Academy of Neurology being held in Washington, D.C. April 18-25.

15 Apr 2015

Existing drug could help treat MS, other neurological diseases

Damage to myelin, the fatty insulator that enables communication between nerve cells, characterizes multiple sclerosis (MS) and other devastating neurological diseases.

3 Mar 2015

Ligand indazole chloride improves motor function, study shows

Multiple sclerosis (MS), an autoimmune disease of the brain and spinal cord, affects about 2.3 million people worldwide (400,000 in the United States). Affecting more women than men, it can be seen at any age, although it is most commonly diagnosed between the ages of 20 and 40.

2 Dec 2014

Asterias, CIRM sign NGA to begin AST-OPC1 study for complete cervical spinal cord injury

Asterias Biotherapeutics, Inc. announced today that the Company has signed a Notice of Grant Award (NGA) with the California Institute of Regenerative Medicine (CIRM), effective October 1, 2014.

20 Oct 2014

Cell transplantation treatment may benefit people with spinal cord injury

Two studies recently published in Cell Transplantation reveal that cell transplantation may be an effective treatment for spinal cord injury (SCI), a major cause of disability and paralysis with no current restorative therapies.

16 Oct 2014

New MS treatment found safe, tolerable in phase I clinical trials

A new treatment under investigation for multiple sclerosis (MS) is safe and tolerable in phase I clinical trials, according to a study published August 27, 2014, in Neurology Neuroimmunology & Neuroinflammation, a new online-only, freely accessible, specialty medical journal.

28 Aug 2014

Asterias receives clearance from FDA to initiate Phase 1/2a clinical trial of AST-OPC1

Asterias Biotherapeutics Inc. has received clearance from the U.S. Food and Drug Administration to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury.

27 Aug 2014

Neuregulin 1 effective in promoting peripheral nerve regrowth

Neuregulin 1 (NRG1) is a pleiotropic factor characterized by the existence of numerous isoforms arising from alternative splicing of exons that confer to the protein deeply different characteristics.

26 Jul 2014

Researchers identify protein that promotes growth of brain cells damaged by MS

Vittorio Gallo, PhD, Director of the Center for Neuroscience Research at Children's National Health System, and other researchers have found a "potentially novel therapeutic target" to reduce the rate of deterioration and to promote growth of brain cells damaged by multiple sclerosis (MS). Current therapies can be effective in patients with relapsing MS, but have little impact in promoting tissue growth.

9 Feb 2014

LA BioMed receives grant to study role of serum Vitamin A in people with multiple sclerosis

Some 2.5 million people around the world have multiple sclerosis (MS), a potentially debilitating disease in which the body's immune system destroys the protective sheath (myelin) that covers nerves.

6 Jan 2014

GeNeuro's GNbAC1 antibody demonstrates safety profile in Phase 2a study for MS

GeNeuro announced today that its GNbAC1 humanized monoclonal antibody was found to have a very good safety profile when administered to patients with relapsing and progressive forms of Multiple Sclerosis as part of a Phase 2a study.

4 Nov 2013

First Direct Measurement Of Spinal Cord Myelin In MS

...

24 Sep 2013

Wayne State University initiates groundbreaking multiple sclerosis study

A groundbreaking study in multiple sclerosis focusing on "remyelination in the brain" has been initiated by Omar Khan, M.D., professor and chair of neurology at the Wayne State University School of Medicine.

19 Sep 2013

UCSF neuroscientist wins Barancik Prize for multiple sclerosis research

Neuroscientist Jonah Chan, PhD, at the University of California, San Francisco, is the first recipient of a new international prize launched to recognize innovation and progress in multiple sclerosis research.

17 Sep 2013

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

Mayo Clinic and Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis.

23 Apr 2013

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Omeros Corporation today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled receptor (GPCR) unlocked by Omeros, significantly improved function from experimental autoimmune encephalomyelitis (EAE) in mice.

11 Apr 2013